| Code | Description | Claims | Beneficiaries | Total Paid |
|---|
| 99283 |
Emergency department visit for the evaluation and management, moderate severity |
7,506 |
6,257 |
$1.03M |
| 99284 |
Emergency department visit for the evaluation and management, high severity |
4,822 |
3,998 |
$1.01M |
| G0463 |
Hospital outpatient clinic visit for assessment and management of a patient |
17,465 |
15,402 |
$777K |
| 99285 |
Emergency department visit for the evaluation and management, high severity with immediate threat to life |
1,332 |
1,072 |
$500K |
| 80053 |
Comprehensive metabolic panel |
3,758 |
3,466 |
$338K |
| U0003 |
Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r |
1,935 |
618 |
$130K |
| 85025 |
Blood count; complete (CBC), automated, and automated differential WBC count |
2,059 |
1,908 |
$116K |
| 96375 |
Therapeutic injection; each additional sequential IV push |
639 |
571 |
$85K |
| 36415 |
Collection of venous blood by venipuncture |
9,628 |
8,600 |
$81K |
| 96374 |
Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance |
617 |
564 |
$57K |
| U0002 |
2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc |
947 |
667 |
$51K |
| 85027 |
|
1,429 |
1,333 |
$49K |
| 96361 |
Intravenous infusion, hydration; each additional hour |
399 |
356 |
$35K |
| C9803 |
Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source |
867 |
839 |
$30K |
| U0005 |
Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 |
1,643 |
496 |
$29K |
| 99282 |
Emergency department visit for the evaluation and management, low to moderate severity |
558 |
538 |
$19K |
| 74177 |
Computed tomography, abdomen and pelvis; with contrast material |
12 |
12 |
$19K |
| 86140 |
|
466 |
425 |
$17K |
| J3490 |
Unclassified drugs |
1,736 |
836 |
$17K |
| Q9967 |
Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml |
101 |
93 |
$16K |
| 85610 |
|
506 |
481 |
$13K |
| 83605 |
|
261 |
211 |
$13K |
| 87631 |
|
73 |
71 |
$13K |
| J7030 |
Infusion, normal saline solution , 1000 cc |
983 |
875 |
$11K |
| 99214 |
Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity |
235 |
217 |
$10K |
| 71045 |
Radiologic examination, chest; single view |
74 |
69 |
$9K |
| 93005 |
Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report |
85 |
81 |
$8K |
| 80307 |
Drug test(s), presumptive, any number of drug classes; immunoassay |
43 |
40 |
$8K |
| 84145 |
|
86 |
83 |
$8K |
| 0002A |
|
295 |
293 |
$5K |
| 96365 |
Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour |
29 |
26 |
$5K |
| 0001A |
|
297 |
285 |
$5K |
| J7040 |
Infusion, normal saline solution, sterile (500 ml = 1 unit) |
505 |
367 |
$5K |
| 83735 |
|
98 |
94 |
$4K |
| 96372 |
Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular |
59 |
51 |
$4K |
| J0696 |
Injection, ceftriaxone sodium, per 250 mg |
140 |
134 |
$3K |
| 84703 |
|
66 |
63 |
$3K |
| 84484 |
|
33 |
24 |
$3K |
| 81001 |
|
79 |
77 |
$2K |
| 84443 |
Thyroid stimulating hormone (TSH) |
78 |
75 |
$2K |
| 80048 |
Basic metabolic panel (calcium, ionized) |
44 |
39 |
$2K |
| 90471 |
Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine |
72 |
60 |
$2K |
| 83036 |
Hemoglobin; glycosylated (A1C) |
49 |
49 |
$2K |
| 99335 |
|
36 |
26 |
$1K |
| G0438 |
Annual wellness visit; includes a personalized prevention plan of service (pps), initial visit |
18 |
17 |
$1K |
| 0241U |
Neonatal screening for hereditary disorders, genomic sequence analysis panel |
14 |
14 |
$1K |
| 80061 |
Lipid panel |
36 |
36 |
$1K |
| 83880 |
|
12 |
12 |
$1K |
| 87502 |
Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets |
14 |
14 |
$1K |
| J1100 |
Injection, dexamethasone sodium phosphate, 1 mg |
41 |
41 |
$1K |
| 83690 |
|
25 |
24 |
$981.91 |
| 90686 |
|
67 |
59 |
$819.50 |
| 85730 |
|
27 |
26 |
$784.61 |
| 87635 |
Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe |
14 |
14 |
$761.56 |
| 84100 |
|
27 |
27 |
$757.71 |
| 99213 |
Office or other outpatient visit for the evaluation and management of an established patient, low complexity |
16 |
15 |
$754.03 |
| 82077 |
|
37 |
36 |
$581.05 |
| 87651 |
Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe |
12 |
12 |
$345.71 |
| 99173 |
|
44 |
39 |
$323.42 |
| 81003 |
|
12 |
12 |
$287.77 |
| 87804 |
Infectious agent antigen detection by immunoassay; Influenza, each type |
43 |
21 |
$237.40 |
| J2272 |
Injection, morphine sulfate (fresenius kabi), not therapeutically equivalent to j2270, up to 10 mg |
17 |
12 |
$188.42 |
| 0003A |
|
16 |
16 |
$161.31 |
| 71046 |
Radiologic examination, chest; 2 views |
15 |
13 |
$145.05 |
| Q0144 |
Azithromycin dihydrate, oral, capsules/powder, 1 gram |
12 |
12 |
$60.95 |
| J7120 |
Ringers lactate infusion, up to 1000 cc |
15 |
14 |
$19.74 |
| A0425 |
Ground mileage, per statute mile |
13 |
12 |
$6.90 |
| 91300 |
|
55 |
54 |
$0.00 |
| A9270 |
Non-covered item or service |
16 |
12 |
$0.00 |